President-elect Trump selected Jay Bhattacharya, Stanford professor and Covid-19 lockdown critic, to lead NIH, and Jim ...
Axsome Therapeutics’ narcolepsy drug AXS-12 hit the primary endpoint in its Phase 3 ENCORE trial, showing a statistically ...
Sarepta Therapeutics and Arrowhead Pharmaceuticals teamed up on an siRNA partnership that has one of the biggest promises of ...
Alladapt Immunotherapeutics, a well-financed biotech working in the food allergy field, shut down following talks with the ...
FDA extends review of Soleno Therapeutics' diazoxide choline extended-release tablets for Prader-Willi syndrome by three ...
Amgen’s long-anticipated weight loss data are here, with MariTide spurring an average of 20% weight loss after one year for ...
Roche's tiragolumab failed to meet overall survival endpoint in Phase 3 SKYSCRAPER-01 trial when combined with Tecentriq for ...
Roche is acquiring its cell therapy and genomic medicines partner Poseida Therapeutics, the companies said Tuesday morning.
Aviceda seeks $200M for AVD-104 trial, Nerviano reacquires NMS-293 from Merck KGaA, MaaT Pharma reports positive Phase 1b ALS drug data, Secretome raises $20.4M, 35Pharma secures $35M Series C, ...
The Biden administration proposed a new rule Tuesday that would expand Medicare and Medicaid coverage of popular ...
Agilent Technologies announced reorganization into three business units: life sciences and diagnostics led by Simon May, ...
Merck is ending Phase 3 trial of Winrevair (sotatercept) early due to positive interim results in treating pulmonary arterial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback